Malignant neoplasm of stomach
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, HBV infection may contribute to a higher risk for GC based on the meta-analysis and to the morphological atypia of gastric epithelium by the histological assessment, and GC patients among HBV carriers showed lower expression of PD-L1 may lose the chance for immune checkpoint blockade therapy.
|
31471921 |
2020 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.
|
31669518 |
2020 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
This suggests that the total number of PD-L1-expressing cells, including tumor and immune cells, is a more sensitive prognostic biomarker than the number of PD-L1-expressing tumor cells in GC.
|
31451991 |
2020 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation.
|
31463730 |
2020 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
By using a panel of PD-L1-expressing human GC cell lines and PD-L1-overexpressing cells, we studied cellular uptake, cytotoxic effects, and cellular apoptosis in the presence of PD-L1 mAb-conjugated NPs.
|
30587982 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical relevance of autophagy-related markers p62/SQSTM1 and LC3 with PD-L1 was evaluated in 137 patients with gastric cancer.
|
30925913 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The molecular subtype of gastric cancers is correlated with the immune subtype, including immune contexture and PD-L1 expression, within the tumor microenvironment.
|
31152268 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a new nova of anti-tumor therapy, immunotherapy has been shown to be effective in many tumors of which PD-1/PD-L1 monoclonal antibodies has been proofed to increase overall survival rate in advanced gastric cancer (GC).
|
31722674 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that tumor PD-L1 positivity was associated with loss of ARID1A and showed trend toward better survival of patients with various molecular subtypes of GC (experimental set, n = 273).
|
30664822 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the real effects of fixation conditions on HER-2 testing or PD-L1 testing for gastric cancer using gastrectomy specimens.
|
30842953 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exosomal PD-L1 was an independent prognostic factor in GC (n = 69, 95% confidence interval = 1.142-7.669, P = 0.026).
|
31087180 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The clinical implications of MSI status and PD-L1 expression in gastric cancer have not been well-elucidated.
|
29727332 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b> PD-L1 monoclonal antibody-conjugated immunoliposomes have immense potential to be applied as a next-generation nanomedicine for PD-L1-positive gastric cancers.
|
31290727 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of PD-L1 in GC tissues was analyzed immunohistochemically.
|
31372044 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PD-L1 membrane expression on tumour cells (TC) and infiltrating immune cells (IC), CD3 + T-lymphocytes, CD8+ cytotoxic T-cells, ATM and HER2 were assessed by immunohistochemistry (IHC) in the ACRG (Asian Cancer Research Group) GC cohort (N = 380).
|
30729066 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
From these data, we infer that MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in GC cells and suggest that MACC1 may be a therapeutic target for GC immunotherapy.
|
31557409 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, PD‑L1 expression was significantly increased in Hp‑positive gastric cancer.
|
31322226 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, combined markers of PD-L1 and MSI or CD8+ TILs may be more useful prognostic biomarkers in gastric cancer, and better clarify the immune status of gastric cancer patients.
|
30874607 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Higher <sup>18</sup>F-FDG accumulation in gastric cancers is correlated with positive PD-L1/PD-L1-TILs expression.
|
31848322 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the tumor microenvironment of gastric cancer is very complex and the association of PD-L1 with the tumor microenvironment in gastric cancer is still not clear.
|
31519868 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
MHC Class 1 and PDL-1 Status of Primary Tumor and Lymph Node Metastatic Tumor Tissue in Gastric Cancers.
|
30881447 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The findings showed that PD-L1 was overexpressed in GC tissues compared with normal mucosa.
|
30565045 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Summing up, heterogeneous or complete loss of ARID1A expression occurred in 14.7% of GCs and correlated with PD-L1 status, indicating potential for future combined anti-PD-L1/ARID1A therapy.
|
31704366 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of PD-L1 on CD4(+) and CD8(+) cells in GC was higher than in the control group (<i>p</i> < 0.0001).
|
31110545 |
2019 |
Malignant neoplasm of stomach
|
0.100 |
Biomarker
|
disease |
BEFREE |
Avelumab is a human IgG1 antibody directed against PD-L1 approved for Merkel cell carcinoma and urothelial carcinoma that could be useful also for the treatment of GC.
|
31060469 |
2019 |